Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 20;27(1):41.
doi: 10.1007/s11894-025-00991-7.

Applying Biomarkers in Treat-to-target Approach for IBD

Megan Lutz  1 , Sara Horst  2 , Freddy Caldera  3
Affiliations
Review

Applying Biomarkers in Treat-to-target Approach for IBD

Megan Lutz et al. Curr Gastroenterol Rep. .

Abstract

Purpose of review: The treatment of inflammatory bowel disease (IBD) has evolved significantly over time based on "treat-to-target", an approach which uses sequential objective makers to monitor response to therapy with the ultimate goal of achieving endoscopic healing. Biomarkers, including C-reactive protein and fecal calprotectin, are an important noninvasive intermediate step in this treatment approach as well as in routine monitoring of disease activity. While widely utilized, there is significant variability and some uncertainty in biomarker implementation; this review summarizes evidence for the use of biomarkers in IBD.

Recent findings: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) update in combination with the 2023 American Gastroenterological Association (AGA) guidelines on the role of biomarkers in the management of both Crohn's disease and ulcerative colitis have offered significant new guidance for those who manage IBD. Biomarkers offer important insight into disease activity and can be used to track progress toward deeper levels of remission in IBD.

Keywords: Biomarkers; C-reactive protein; Fecal calprotectin; Treat-to-target.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Ulcerative colitis and Crohn’s disease treatment recommendations in setting of elevated biomarkers based on clinical presentation. In patients with calprotectin over 150 μg/g or CRP > 5 mg/L, assess symptom status. Those who are asymptomatic may require endoscopic assessment for further evaluation or short interval repeat biomarkers. Those with mild symptoms typically require endoscopic assessment (see second bullet point in special circumstances). Those with moderate to severe symptoms, may undergo therapy adjustment (i.e. check drug levels and adjust) or endoscopic evaluation if options for changes in therapy are limited or endoscopy is needed for other reasons (i.e. rule out CMV). Pouchitis recommendations are discussed in the text. Abbreviations: CRP: C reactive protein, FC: fecal calprotectin, CMV: cytomegalovirus
See this image and copyright information in PMC

References

    1. Gracie DJ, Williams CJM, Sood R, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol. 2016;111(4):541–51. 10.1038/ajg.2016.59. - DOI - PubMed
    1. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–38. 10.1038/ajg.2015.233. - DOI - PubMed
    1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83. 10.1053/j.gastro.2020.12.031. - DOI - PubMed
    1. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease. Inflamm Bowel Dis. 2009;15(9):1295–301. 10.1002/ibd.20927. - DOI - PubMed
    1. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463–8. 10.1053/j.gastro.2009.09.056. - DOI - PubMed

MeSH terms